Shares of Charles River Laboratories International Inc. CRL slipped 1.13% to $164.97 Friday, on what proved to be an ...

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call ...

Shares of Charles River Laboratories International Inc. CRL slipped 1.33% to $163.64 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index ...

Fifth Third Bancorp cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

Atomi Financial Group Inc. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

BofA lowered the firm’s price target on Charles River (CRL) to $195 from $210 and keeps a Neutral rating on the shares. The firm updated its ...

William Blair downgraded Charles River Laboratories to market perform citing concerns over a decline in early-stage R&D funding from large pharmas. Read more here.

Bank of America Securities analyst Juan Avendano reiterated a Hold rating on Charles River Labs (CRL – Research Report) today and set a price ...

Charles River Laboratories International, Inc. CRL has introduced Apollo for CRADL (Charles River Accelerator and Development Lab), a secure cloud-based platform that enhances leading vivarium rental ...

Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. Valued at $8.6 billion by ...

Demand slipped for several large contract research organizations last year, and a new report from William Blair analysts suggests these firms should brace for a similar R&D landscape in 2025.